{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:57:55Z","timestamp":1780927075352,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"23-24","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","award":["IGA MZCR NS9627"],"award-info":[{"award-number":["IGA MZCR NS9627"]}],"id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministerstvo \u0160kolstv\u00ed, Ml\u00e1de\u017ee a T\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["MSM 6198959205"],"award-info":[{"award-number":["MSM 6198959205"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.cca.2010.08.014","type":"journal-article","created":{"date-parts":[[2010,8,14]],"date-time":"2010-08-14T05:09:28Z","timestamp":1281762568000},"page":"1957-1962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma"],"prefix":"10.1016","volume":"411","author":[{"given":"Kate\u0159ina","family":"Mi\u010dov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Friedeck\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Pol\u00fdnkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2010.08.014_bb0005","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukaemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.cca.2010.08.014_bb0010","first-page":"1330","article-title":"Tyrosne kinase activity and transformation potency of bcr\u2013abl oncogene products","volume":"340","author":"Lugo","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.cca.2010.08.014_bb0015","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.cca.2010.08.014_bb0020","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia Net","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2010.08.014_bb0025","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR\u2013ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.cca.2010.08.014_bb0030","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cca.2010.08.014_bb0035","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy in chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2010.08.014_bb0040","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1570-0232(03)00518-X","article-title":"Direct and fast capillary zone electrophoresic method for the determination of Gleevec and its main metabolite in human urine","volume":"794","author":"Rodr\u00edguez-Flores","year":"2003","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.cca.2010.08.014_bb0045","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.chroma.2004.09.089","article-title":"Nonaqueous capillary electrophoresis metod for the analysis of gleevec and its main metabolite in human urine","volume":"1068","author":"Rodr\u00edguez-Flores","year":"2005","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.cca.2010.08.014_bb0050","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.jchromb.2009.04.028","article-title":"New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma","volume":"877","author":"De Francia","year":"2009","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.cca.2010.08.014_bb0055","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/01.ftd.0000175973.71140.91","article-title":"Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"27","author":"Titier","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cca.2010.08.014_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1570-0232(03)00206-X","article-title":"Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma","volume":"791","author":"Parise","year":"2003","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.cca.2010.08.014_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jchromb.2004.01.006","article-title":"Determination of imatinib (Gleevec\u00ae) in human plasma by solid-phase extraction \u2013 liquid chromatography \u2013 ultraviolet absorbance detection","volume":"803","author":"Widmer","year":"2004","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.cca.2010.08.014_bb0070","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.cca.2009.10.007","article-title":"Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS\/MS","volume":"411","author":"Roth","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2010.08.014_bb0075","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.cca.2010.08.014_bb0080","unstructured":"Kutsev S, Kravchenko E, Turkina A. Imatinib blood level test in Russian federation. EUTOS Blood Level Testing Summit, November 16\u201317, 2009, Bordeaux, France (lecture)."},{"key":"10.1016\/j.cca.2010.08.014_bb0085","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jchromb.2004.01.032","article-title":"Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples","volume":"804","author":"Velpandian","year":"2004","journal-title":"J Chromatogr B"},{"key":"10.1016\/j.cca.2010.08.014_bb0090","series-title":"Guidance for Industry","author":"FDA","year":"2001"},{"key":"10.1016\/j.cca.2010.08.014_bb0095","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1023\/A:1007669411738","article-title":"Bioanalytical method validation \u2014 a revisit with a decade of progress","volume":"17","author":"Shah","year":"2000","journal-title":"Pharmaceut Res"},{"key":"10.1016\/j.cca.2010.08.014_bb0100","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2010.08.014_bb0105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0731-7085(02)00080-8","article-title":"Quantification of the anti-leukemia drug STI571 (Gleevec\u2122) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry","volume":"28","author":"Bakhtiar","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.cca.2010.08.014_bb0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cca.2010.08.014_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of \u03b11-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110005115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110005115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:00:36Z","timestamp":1762113636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898110005115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":23,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0009898110005115"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2010.08.014","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2010.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}